Biogen Latvia is a US-based company and one of the world's largest biotechnology companies for the development and commercialization of therapies specializing in neurological disease research. Biogen was founded in 1978 and is one of the largest biotech companies, employing more than 7400 employees worldwide. The company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. Biogen's turnover in 2019 was 14.4 billion US dollars.